Use of oral contraceptives in the treatment of women with polycystic ovary syndrome

References

• Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol.29, 181–191 (1935).
   Google Scholar
• Kalro BN, Loucks TL, Berga SL. Neuromodulation in polycystic ovary syndrome. Obstet. Gynecol. Clin. North Am.28, 35–62 (2001).
   PubMedGoogle Scholar
• Ayala C, Steinberger E, Smith KD, Rodriguez-Rigau LJ, Petak SM. Serum testosterone levels and reference ranges in reproductive-age women. Endocr. Pract.5(6), 322–329 (1999).
   PubMedGoogle Scholar
• Azziz R, Carmina E, Dewailly D et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J. Clin. Endocrinol. Metab.11, 4237–4245 (2006).
   Google Scholar
• Azizz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J. Clin. Endocrinol. Metab.89, 2745–2749 (2004).
   PubMedGoogle Scholar
• Legro RS. Pregnancy consideration in women with polycystic ovary syndrome. Clin. Obstet. Gynecol.50, 295–304 (2007).
   PubMed Web of Science ®Google Scholar
• Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes38, 1165–1174 (1989).
   PubMed Web of Science ®Google Scholar
• Carmina E, Lobo RA. Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. Fertil. Steril.82, 661–665 (2004).
   PubMed Web of Science ®Google Scholar
• DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil. Steril.83, 1454–1460 (2004).
   Google Scholar
• Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care22, 141–146 (1999).
   PubMed Web of Science ®Google Scholar
• Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults and the Adult Treatment Panel III (ATP III). Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome. Diabetes Care28, 1769–1779 (2005).
   PubMed Web of Science ®Google Scholar
• Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.90, 1929–1935 (2005).
   PubMed Web of Science ®Google Scholar
• Wild R. Long-term health consequences of PCOS. Hum. Reprod. Update8, 231–241 (2002).
   PubMed Web of Science ®Google Scholar
• Topcu S, Caliskan M, Ozcimen EE et al. Do young women with polycystic ovary syndrome show early evidence of preclinical coronary artery disease? Hum. Reprod.21(4), 930–935 (2006).
   PubMed Web of Science ®Google Scholar
• Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF, Fitzpatrick LA. Prevalence and predictors of coronary artery calcification in women with polycystic ovary disease. J. Clin. Endocrinol. Metab.88, 2562–2568 (2003).
   PubMed Web of Science ®Google Scholar
• Guzick DS. Ovulation induction management of PCOS. Clin. Obstet. Gynecol.50, 255–267 (2007).
   PubMed Web of Science ®Google Scholar
• Gambineri A, Patton L, Vaccina A et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J. Clin. Endocrinol. Metab.91, 3970–3980 (2006).
   PubMed Web of Science ®Google Scholar
• Schindler AE, Capagnoli C, Druckmann R et al. Classification and pharmacology of progestins. Maturitas46, 7–16 (2003).
   PubMed Web of Science ®Google Scholar
• Ehrmann DA. Polycystic ovary syndrome. N. Engl. J. Med.352, 1223–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Azziz R. The evaluation and mangement of hirsutism. Obstet. Gynecol.101, 995–1007 (2003).
   PubMed Web of Science ®Google Scholar
• Geffner ME, Kaplan SA, Bersch N et al. Persistence of insulin resistance in polycystic ovary disease after inhibition of ovarian steroid secretion. Fertil. Steril.45, 327–333 (1986).
   PubMed Web of Science ®Google Scholar
• Rimm EB, Manson JE, Stampfer MJ et al. Oral contraception use and the risk of type 2 diabetes in a large prospective study of women. Diabetologia35, 967–972 (1992).
   PubMed Web of Science ®Google Scholar
• Chasen-Taber L, Willet WC, Stampfer MJ et al. A prospective study of oral contraceptives and NIDDM among U.S. women. Diabetes20, 330–335 (1997).
   Google Scholar
• Troisi RJ, Cowie CC, Harris MI. Oral contraceptive use and glucose metabolism in a national sample of women in the United States. Am. J. Obstet. Gynecol.183, 389–395 (2000).
   PubMed Web of Science ®Google Scholar
• Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J. Intern. Med. Suppl.738, 1–60 (1996).
   PubMedGoogle Scholar
• Petersen KR, Christiansen E, Madsbad S, Skouby SO, Andersen LF, Jespersen J. Metabolic and fibrinolytic response to changed insulin sensitivity in users of oral contraceptives. Contraception60, 337–344 (1999).
   PubMedGoogle Scholar
• Scheen AJ, Jandrain BJ, Humblet DMP, Jaminet CB, Gaspard UJ, Lefebvre PJ. Effects of a 1 year treatment with a low-dose combined oral contraceptive containing ethinyl estradiol and cyproterone acetate on glucose and insulin metabolism. Fertil. Steril.59, 797–802 (1993).
   PubMed Web of Science ®Google Scholar
• Perseghin G, Scifo P, Pagliato E et al. Gender factors affecting fatty acids-induced insulin resistance in non-obese humans: effects of oral steroidal contraception. J. Clin. Endocrinol. Metab.86, 3188–3196 (2001).
   PubMed Web of Science ®Google Scholar
• Pasquali R, Gambineri A, Anconetani B et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen–progestagen treatment. Clin. Endocrinol.50, 517–527 (1999).
   PubMed Web of Science ®Google Scholar
• Escobar-Morreale H, Lasuncion MA, Sancho J. Treatment of hirsutism with ethinyl/estradiol – desogestal contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil. Steril.74, 816–819 (2000).
   PubMed Web of Science ®Google Scholar
• Cagnacci A, Paoletti AM, Renzi A et al. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J. Clin. Endocrinol. Metab.88, 3621–3625 (2003).
   PubMed Web of Science ®Google Scholar
• Falsetti L, Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand.74, 56–60 (1995).
   PubMed Web of Science ®Google Scholar
• Armstrong VL, Wiggam MI, Ennis CN et al. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl/estradiol/cyproterone acetate. Q. J. Med.94, 31–37 (2001).
   Google Scholar
• Cibula D, Fanta M, Hill M, Sindelka A, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low androgenic progestin. Hum. Reprod.17, 76–82 (2002).
   PubMed Web of Science ®Google Scholar
• Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum. Reprod.17, 1729–1737 (2002).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol–cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.88, 148–156 (2003).
   PubMed Web of Science ®Google Scholar
• Sabuncu T, Harma M, Harma M, Nazligul Y, Kilic F. Sibutramine has a positive effect on clinical and metabolic parameters in obese patients with polycystic ovary syndrome. Fertil. Steril.80, 1199–1204 (2003).
   PubMed Web of Science ®Google Scholar
• Guido M, Romualdi D, Giuliani M et al. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J. Clin. Endocrinol. Metab.89, 2817–2283 (2004).
   PubMed Web of Science ®Google Scholar
• Cibula D, Fanta M, Vrbikova J et al. The effect of combination therapy with metformin and combined oral contraceptives versus combined oral contraceptives alone on insulin sensitivity, hyperandrogenemia, SHBG and lipids in PCOS patients. Hum. Reprod.20(1), 180–184 (2005).
   PubMed Web of Science ®Google Scholar
• Korytkowski MT, Mokan M, Horwitz M, Berga SL. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab.80, 3327–3334 (1995).
   PubMed Web of Science ®Google Scholar
• Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl/estradiol cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrinol. Metab.85, 3161–3168 (2000).
   PubMed Web of Science ®Google Scholar
• Palep-Singh M, Barth JH, Mook K, Balen AH. An observational study of Yasmin in the management of polycystic ovary syndrome. J. Fam. Plann. Reprod. Health Care30, 163–165 (2004).
   PubMed Web of Science ®Google Scholar
• Vrbikova J, Stanicka S, Dvorakova K et al. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in combination with peroral cyproterone acetate in women with polycystic ovary syndrome. Eur. J. Endocrinol.150, 215–223 (2004).
   PubMed Web of Science ®Google Scholar
• Nader S, Riad-Gabriel MG, Saad MF. The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J. Clin. Endocrinol. Metab.82, 3074–3077 (1997).
   PubMed Web of Science ®Google Scholar
• Costello MF, Shrestha B, Eden J, Johnson NP, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. Hum. Reprod. DOI: 0: dem005v1-10 (2007) (Epub ahead of print).
   PubMedGoogle Scholar
• Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis. Hum. Reprod.22, 317–322 (2007).
   PubMed Web of Science ®Google Scholar
• Burkman RT, Collins JA, Shulman LP, Williams JK. Current perspectives on oral contraceptive use. Am. J. Obstet. Gynecol.185, S4–S12 (2001).
   PubMed Web of Science ®Google Scholar
• ACOG Practice Bulletin 18. The use of hormonal contraception in women with coexisting medical conditions. Int. J. Gynaecol. Obstet.75, 93–106 (2001).
   PubMed Web of Science ®Google Scholar
• Van Rooijen M, Schoultz BV, Silveira A, Hamsten A, Bremme K. Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VII. Am. J. Obstet. Gynecol.186, 44–48 (2002).
   PubMed Web of Science ®Google Scholar
• Baillargeon J-P, McClish DK, Essah PA, Nestler JE. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis. J. Clin. Endocrinol. Metab.90, 3863–3870 (2005).
   PubMed Web of Science ®Google Scholar
• Petitti DB, Sidney S, Quesenberry CP, Bernstein A. Incidence of stroke and myocardial infarction in women of reproductive age. Stroke28, 280–283 (1997).
   PubMed Web of Science ®Google Scholar